Skip to main content

Table 1 Demographic and clinical variables of patients

From: An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab

Diagnosis Number of patients Gender (Female/Male) Mean age at inclusion +/- SD (range)
Group 1: NMO 16 13/3 55.02 +/- 9.80
    (40-63)
Group 2: MS 85 60/25 39.43 +/-9.40
(18-76)
 - Relapsing-remitting MS 72   
 - Secondary progressive MS 3   
 - Primary progressive MS 10   
Group 3: idiopathic ON 24 17/7 35.01 +/- 11.39
(14-62)
 -Isolated episode 15   
 -Recurrent idiopathic ON 9   
Group 4: idiopathic myelitis 21 14/7 46.30 +/- 14.27
(21-68)
 -Isolated episode: 18   
  > 3 vertebral segments 9   
  ≤ 3 vertebral segments 9   
 -Recurrent idiopathic myelitis 3   
Group 5: other neurological disorders 13 7/6 50.45 +/- 6.11
(42-59)
 -Myelitis associated with lupus 2   
 -ON associated with Sjögren syndrome 1   
 -Multifocal motor neuropathy 2   
 -CIDP 1   
 -Spinal infarction 2   
 -Ischemic optic neuropathy 5   
Group 6: healthy controls 8 5/3 34.45 +/- 8.31
    (27-50)
  1. SD; standard deviation; NMO: neuromyelitis; MS: multiple sclerosis; ON: optic neuritis; CIDP: chronic inflammatory demyelinating polyneuropathy).